Intellia Therapeutics Inc. Earnings

Intellia Therapeutics Inc.’s revenue jumped 104.76% since last year same period to $14.25Mn in the Q2 2025. On a quarterly growth basis, Intellia Therapeutics Inc. has generated -14.33% fall in its revenue since last 3-months.

Intellia Therapeutics Inc.’s net profit jumped 31.11% since last year same period to $-101.26Mn in the Q2 2025. On a quarterly growth basis, Intellia Therapeutics Inc. has generated 11.44% jump in its net profits since last 3-months.

Intellia Therapeutics Inc.’s net profit margin jumped 66.35% since last year same period to -710.81% in the Q2 2025. On a quarterly growth basis, Intellia Therapeutics Inc. has generated -3.37% fall in its net profit margins since last 3-months.

Intellia Therapeutics Inc.’s earning per share (EPS) estimates for the current quarter stand at -1 - a 3.1% jump from last quarter’s estimates.

Intellia Therapeutics Inc.’s earning per share (EPS) estimates for the current year stand at -1.

Intellia Therapeutics Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Intellia Therapeutics Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.